Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Investor Presentation (May 2024)
11 slides from Ac Immune Sa's investor presentation, May 2024
Slide 1: Pioneering Precision Medicine
COMBINING DIAGNOSTICS AND THERAPEUTICS PIONEERING PRECISION MEDICINE Abeta active immunotherapy agreement with Takeda NASDAQ: ACIU | Investor Presentation - May 2024 NASDAQ: ACIU | Investor Presentation, May 2024 © 2024 AC Immune. Not to be used or reproduced without permission
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include s
Slide 3: Pioneering Precision Medicine
COMBINING DIAGNOSTICS AND THERAPEUTICS PIONEERING PRECISION MEDICINE Abeta active immunotherapy agreement with Takeda NASDAQ: ACIU | Investor Presentation - May 2024 NASDAQ: ACIU | Investor Presentation, May 2024 © 2024 AC Immune. Not to be used or reproduced without permission
Slide 4: Unique Abeta targeted active immunotherapy – ACI-24.060
Unique Abeta targeted active immunotherapy – ACI-24.060 Best-in-class SupraAntigen®-based active immunotherapy in Phase 2 ■ Generates antibody responses against toxic forms of Abeta (oligomeric and pyroGlu-Abeta) ■ FDA Fast Track supports disruptive potential in Alzheimer’s disease treatment and pre
Slide 5: Landmark deal for ACI-24.060 in Alzheimer's disease
Landmark deal for ACI-24.060 in Alzheimer’s disease Supports promise of active immunization for neurodegenerative diseases ■ Today’s deal with Takeda covers AC Immune’s unique, class-leading Abeta targeted active immunotherapy ACI-24.060 ■ Deal terms: ▪ $100 million upfront payment received for excl
Slide 6: Biomarker-based Phase 1b/2 study of ACI-24.060 in AD and DS
: Biomarker-based Phase 1b/2 study of ACI-24.060 in AD1 and DS2 Placebo-controlled Phase 1b/2 Study Overview Trial Schematic Dose escalation in AD Follow up / expansion phase in AD Adaptive Study Design ▪ Interim analyses of safety/tolerability & immunogenicity Treatment in AD4 Both Follow up ▪ Biom
Slide 7: AC Immune technology platforms driving validating pharma deals
AC Immune technology platforms driving validating pharma deals Strategy: optimize value to risk ratio and retain significant upside Platform SupraAntigen® Morphomer® Program ACI-24.060 ACI-35.030 Mor Tau Tau PET Partner clinical trials clinical trials clinical trials clinical trials ■ An integrated
Slide 8: AC Immune strong track record in deals with leading pharma co.s
AC Immune strong track record in deals1 with leading pharma co.s Strategy: optimize value to risk ratio and retain significant upside Milestones Program Phase Total value2 Upfront2 Royalties Partner received2 ACI-24.060 Phase 1b/2 >USD 2,100 USD 100 Mid-to-high teens (anti-Abeta active immunotherapy
Slide 9: AC Immune technology platforms driving validating pharma deals
AC Immune technology platforms driving validating pharma deals Strategy: optimize value to risk ratio and retain significant upside Platform SupraAntigen® Morphomer® Unpartnered ■ a-syn active immunotherapy ■ Mor-a-syn Programs ■ Anti-TDP-43 mAb1 ■ Mor-TDP-43 PET ■ Anti-NLRP3-ASC mAb ■ Mor-NLRP3-ASC
Slide 10: Conclusions
Conclusions AC Immune’s leadership in precision medicine Significant shareholder value is created through class-leading active immunotherapies in neurodegeneration ▪ Today’s Takeda deal reinforces AC Immune’s track record in deal execution ▪ >USD 4.5 billion in potential milestones from partnerships
Slide 11: AC Immune: Pioneering science and precision medicine
AC Immune: Pioneering science and precision medicine Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention NASDAQ: ACIU | Investor Presentation, May 2024 © 2024 AC Immune. Not to be used or reproduced without permission 11